| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $17.2M | -11.0% | +5.9% |
| SG&A Expense | $6.6M | -2.4% | +11.2% |
| Operating Income | -$23.8M | +8.8% | -7.3% |
| Net Income | -$21.0M | +4.8% | -3.6% |
| EPS (Basic) | -$0.99 | +5.7% | +16.8% |
| EPS (Diluted) | -$0.99 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $71.0M | +20.7% | +6.6% |
| Short-term Investments | $194.4M | -9.9% | +168.7% |
| Current Assets | $270.5M | -3.0% | +88.3% |
| Total Assets | $287.8M | -3.2% | +75.4% |
| Current Liabilities | $14.7M | -4.7% | -6.9% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$59.7M | — | — |
| Capital Expenditures | $1.1M | — | — |
| Investing Cash Flow | -$15.6M | — | — |
| Financing Cash Flow | $9.8M | — | — |
| Free Cash Flow | -$60.8M | — | — |
| +16.8% |
| $22.3M |
| -7.4% |
| -16.5% |
| Stockholders' Equity | $265.5M | -2.8% | +93.2% |